• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Buoyed by new data, Santhera preps filing for DMD drug vamorolone

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 23, 2021 at 10:12: AM
via A year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular dystrophy (DMD) therapy idebenone. Now, it’s ready to file replacement drug vamorolone, armed with new data from a pivotal trial, in what looks like a reversal of its fortunes.

article source
 




Top Bottom
Back
Quote